Using Nicotinamide-Riboside and Pterostilbene to treat osteoarthritis
Development of Nicotinamide-Riboside plus Pterostilbene as a Disease Modifying Osteoarthritis Therapeutic
['FUNDING_OTHER'] · ELYSIUM HEALTH, INC. · NIH-10699600
This study is looking at a new way to help people with osteoarthritis by using a combination of two compounds that might slow down or even improve the condition, aiming to make your joints feel better and work more effectively.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ELYSIUM HEALTH, INC. (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10699600 on ClinicalTrials.gov |
What this research studies
This research investigates a new treatment approach for osteoarthritis (OA) by combining two compounds, Nicotinamide-Riboside and Pterostilbene, which may help slow or reverse the progression of the disease. Osteoarthritis is a common joint condition that causes pain and disability, particularly in older adults. The study aims to enhance cellular function and reduce inflammation in the joints by increasing levels of NAD+, a vital molecule for cellular health. By focusing on the underlying mechanisms of OA, this research seeks to develop a therapy that modifies the disease rather than just alleviating symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with osteoarthritis, particularly those over the age of 65 who are experiencing joint pain and disability.
Not a fit: Patients with osteoarthritis who are not responsive to new therapeutic approaches or those with advanced joint degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new disease-modifying treatment for osteoarthritis, improving quality of life for millions of patients.
How similar studies have performed: While the approach of using NAD+ precursors and sirtuin activators is promising, it is still relatively novel and has not been extensively tested in the context of osteoarthritis.
Where this research is happening
NEW YORK, UNITED STATES
- ELYSIUM HEALTH, INC. — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DELLINGER, RYAN WILLIAM — ELYSIUM HEALTH, INC.
- Study coordinator: DELLINGER, RYAN WILLIAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.